electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
October 11 2023 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced the United States
Patent and Trademark Office has issued a patent related to a
treatment protocol for nVNS.
U.S. Patent No. 11,779,756 entitled “Systems and Methods for
Vagal Nerve Stimulation” was issued on October 10, 2023, and is
generally related to a preferable treatment paradigm for nVNS that
involves applying a single dose of stimulation for about 90 seconds
to about 150 seconds, 2-4 times during a 24-hour period.
“Our intellectual property portfolio continues to grow,” stated
Dan Goldberger, Chief Executive Officer of electroCore. “This new
patent strengthens our position around the application of
non-invasive vagus nerve stimulation, and how frequently nVNS may
be used by a patient or customer looking for relief.”
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans including potential commercial
applications of nVNS and treatment paradigms; its pipeline or
potential markets for its technologies; the timing, outcome and
impact of regulatory, clinical and commercial developments; the
issuance of U.S. and international patents, including patents
related to non-invasive nerve stimulation with mobile devices,
providing expanded IP coverage; the possibility of future business
models, the potential of nVNS generally and gammaCore in particular
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"expects," "believes," "intends," other words of similar meaning,
derivations of such words and the use of future dates. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the ability to obtain additional financing necessary to
continue electroCore's business, sales and marketing and product
development plans, the uncertainties inherent in the development of
new products or technologies, the ability to successfully
commercialize gammaCore™, competition in the industry in which
electroCore operates and general market conditions. All
forward-looking statements are made as of the date of this press
release, and electroCore undertakes no obligation to update
forward-looking statements or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should refer to
all information set forth in this document and should also refer to
the disclosure of risk factors set forth in the reports and other
documents electroCore files with the SEC, available at
www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Apr 2024 to May 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From May 2023 to May 2024